📊 TVGNW Key Takeaways
Is Tevogen Bio Holdings Inc. (TVGNW) a Good Investment?
Tevogen Bio is in critical financial distress with negative stockholders equity of -$8.2M, zero cash reserves, and severe liquidity crisis (current ratio 0.22x). The company burns -$12.4M annually in free cash flow against near-zero revenue, creating imminent insolvency risk without immediate capital infusion.
Tevogen Bio Holdings Inc. Key Strengths (TVGNW)
- Marginal net loss improvement of 2.1% YoY indicates some cost control efforts
- Biotech sector structure allows for potential value creation if clinical/commercial progress is achieved
- Basic financial reporting infrastructure maintained
TVGNW Stock Risks: Tevogen Bio Holdings Inc. Investment Risks
- Negative stockholders equity (-$8.2M) indicates technical insolvency
- Zero cash reserves combined with -$12.4M annual free cash burn creates critical liquidity crisis
- Current ratio of 0.22x demonstrates inability to meet short-term obligations
- Negative revenue of -$195.6K suggests operational distress
- High bankruptcy risk without immediate debt restructuring or capital raise
Key Metrics to Watch
- Cash position and months of runway remaining
- Stockholders equity recovery path and balance sheet restructuring
- Revenue inflection point and transition to positive operating cash flow
- Capital raise announcements or debt restructuring actions
Tevogen Bio Holdings Inc. (TVGNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 6,335.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
TVGNW Profit Margin, ROE & Profitability Analysis
TVGNW vs Healthcare Sector: How Tevogen Bio Holdings Inc. Compares
How Tevogen Bio Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tevogen Bio Holdings Inc. Stock Overvalued? TVGNW Valuation Analysis 2026
Based on fundamental analysis, Tevogen Bio Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tevogen Bio Holdings Inc. Balance Sheet: TVGNW Debt, Cash & Liquidity
TVGNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tevogen Bio Holdings Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.50 indicates the company is currently unprofitable.
TVGNW Revenue Growth, EPS Growth & YoY Performance
Tevogen Bio Holdings Inc. Dividends, Buybacks & Capital Allocation
TVGNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tevogen Bio Holdings Inc. (CIK: 0001860871)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TVGNW
What is the AI rating for TVGNW?
Tevogen Bio Holdings Inc. (TVGNW) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TVGNW's key strengths?
Claude: Marginal net loss improvement of 2.1% YoY indicates some cost control efforts. Biotech sector structure allows for potential value creation if clinical/commercial progress is achieved.
What are the risks of investing in TVGNW?
Claude: Negative stockholders equity (-$8.2M) indicates technical insolvency. Zero cash reserves combined with -$12.4M annual free cash burn creates critical liquidity crisis.
What is TVGNW's revenue and growth?
Tevogen Bio Holdings Inc. reported revenue of $-195.6K.
Does TVGNW pay dividends?
Tevogen Bio Holdings Inc. does not currently pay dividends.
Where can I find TVGNW SEC filings?
Official SEC filings for Tevogen Bio Holdings Inc. (CIK: 0001860871) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TVGNW's EPS?
Tevogen Bio Holdings Inc. has a diluted EPS of $-8.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TVGNW's fundamental grade?
Based on our AI fundamental analysis in June 2026, Tevogen Bio Holdings Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TVGNW stock overvalued or undervalued?
Valuation metrics for TVGNW: ROE of N/A (sector avg: 15%), net margin of 13,432.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TVGNW's AI grade for 2026?
Our dual AI analysis gives Tevogen Bio Holdings Inc. a combined D grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TVGNW's free cash flow?
Tevogen Bio Holdings Inc.'s operating cash flow is $-12.3M, with capital expenditures of $64.4K. FCF margin is 6,335.3%.
How does TVGNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13,432.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.22 (avg: 2).